...
search icon
capr-img

Capricor Therapeutics Inc, Common Stock

CAPR

NAQ

$10.48

+$0.23

(2.24%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$473.99M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
994.42K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.86
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.52 L
$23.4 H
$10.48

About Capricor Therapeutics Inc, Common Stock

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCAPRSectorS&P500
1-Week Return-4.81%-3.24%-2.29%
1-Month Return-18.32%-5.96%5.13%
3-Month Return-27.12%-11.47%-1.04%
6-Month Return-44.96%-11.3%-3.3%
1-Year Return71.8%-8.64%9.3%
3-Year Return187.91%-2.75%39.44%
5-Year Return120.86%29.73%90.79%
10-Year Return-82.24%73.6%173.11%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue310.25K244.90K2.55M25.18M22.27M[{"date":"2020-12-31","value":1.23,"profit":true},{"date":"2021-12-31","value":0.97,"profit":true},{"date":"2022-12-31","value":10.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":88.45,"profit":true}]
Cost of Revenue8.46M245.70K694.87K1.07M1.43M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.91,"profit":true},{"date":"2022-12-31","value":8.22,"profit":true},{"date":"2023-12-31","value":12.64,"profit":true},{"date":"2024-12-31","value":16.85,"profit":true}]
Gross Profit310.25K244.90K2.55M25.18M22.27M[{"date":"2020-12-31","value":1.23,"profit":true},{"date":"2021-12-31","value":0.97,"profit":true},{"date":"2022-12-31","value":10.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":88.45,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses14.00M21.18M32.25M49.26M64.84M[{"date":"2020-12-31","value":21.59,"profit":true},{"date":"2021-12-31","value":32.67,"profit":true},{"date":"2022-12-31","value":49.74,"profit":true},{"date":"2023-12-31","value":75.97,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(13.69M)(20.94M)(29.70M)(24.08M)(42.56M)[{"date":"2020-12-31","value":-1368997100,"profit":false},{"date":"2021-12-31","value":-2093844200,"profit":false},{"date":"2022-12-31","value":-2969738300,"profit":false},{"date":"2023-12-31","value":-2407785900,"profit":false},{"date":"2024-12-31","value":-4256484200,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(13.66M)(20.02M)(29.02M)(22.29M)(40.47M)[{"date":"2020-12-31","value":-1365702800,"profit":false},{"date":"2021-12-31","value":-2002252000,"profit":false},{"date":"2022-12-31","value":-2901953200,"profit":false},{"date":"2023-12-31","value":-2228754200,"profit":false},{"date":"2024-12-31","value":-4046718600,"profit":false}]
Income Taxes(176.83K)(613.41K)(677.85)(2.00)-[{"date":"2020-12-31","value":-17683300,"profit":false},{"date":"2021-12-31","value":-61341200,"profit":false},{"date":"2022-12-31","value":-67785,"profit":false},{"date":"2023-12-31","value":-200,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(13.66M)(20.02M)(29.02M)(29.25M)(40.47M)[{"date":"2020-12-31","value":-1365702800,"profit":false},{"date":"2021-12-31","value":-2002252000,"profit":false},{"date":"2022-12-31","value":-2901953200,"profit":false},{"date":"2023-12-31","value":-2924636500,"profit":false},{"date":"2024-12-31","value":-4046718600,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(13.66M)(20.02M)(29.02M)(22.29M)(40.47M)[{"date":"2020-12-31","value":-1365702800,"profit":false},{"date":"2021-12-31","value":-2002252000,"profit":false},{"date":"2022-12-31","value":-2901953200,"profit":false},{"date":"2023-12-31","value":-2228754200,"profit":false},{"date":"2024-12-31","value":-4046718600,"profit":false}]
EPS (Diluted)(0.94)(0.87)(1.18)(0.87)(1.20)[{"date":"2020-12-31","value":-94,"profit":false},{"date":"2021-12-31","value":-87,"profit":false},{"date":"2022-12-31","value":-118,"profit":false},{"date":"2023-12-31","value":-87,"profit":false},{"date":"2024-12-31","value":-120,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CAPR
Cash Ratio 6.48
Current Ratio 6.55

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CAPR
ROA (LTM) -35.24%
ROE (LTM) -75.39%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CAPR
Debt Ratio Lower is generally better. Negative is bad. 0.17
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.83

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CAPR
Trailing PE NM
Forward PE NM
P/S (TTM) 26.98
P/B 3.67
Price/FCF NM
EV/R 18.72
EV/Ebitda NM
PEG NM

FAQs

What is Capricor Therapeutics Inc share price today?

Capricor Therapeutics Inc (CAPR) share price today is $10.48

Can Indians buy Capricor Therapeutics Inc shares?

Yes, Indians can buy shares of Capricor Therapeutics Inc (CAPR) on Vested. To buy Capricor Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CAPR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Capricor Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Capricor Therapeutics Inc (CAPR) via the Vested app. You can start investing in Capricor Therapeutics Inc (CAPR) with a minimum investment of $1.

How to invest in Capricor Therapeutics Inc shares from India?

You can invest in shares of Capricor Therapeutics Inc (CAPR) via Vested in three simple steps:

  • Click on Sign Up or Invest in CAPR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Capricor Therapeutics Inc shares
What is Capricor Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Capricor Therapeutics Inc (CAPR) is $23.4. The 52-week low price of Capricor Therapeutics Inc (CAPR) is $3.52.

What is Capricor Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Capricor Therapeutics Inc (CAPR) is 3.67

What is the Market Cap of Capricor Therapeutics Inc?

The market capitalization of Capricor Therapeutics Inc (CAPR) is $473.99M

What is Capricor Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Capricor Therapeutics Inc is CAPR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top